PMPRB continues plan to drive down drug prices as patients suffer: Nigel Rawson and John Adams for Inside Policy
By Nigel Rawson and John Adams, November 23, 2022 For seven years, the Patented Medicines Prices Review Board (PMPRB) – ...
Tag: PMPRB
The Patented Medicine Prices Review Board has lost its way (again)
By W. Neil Palmer November 1, 2022 PDF of commentary The Patented Medicine Prices Review Board (PMPRB) is once again ...
Why Canada Should Pay More for Medications: Richard C. Owens in the Wall Street Journal
This article originally appeared in the Wall Street Journal. Below is an excerpt from the article, which can be read ...
Exposing 12 myths that support drug price controls and harm our health system
OTTAWA, ON (June 28, 2022): Is the Patented Medicine Prices Review Board (PMPRB) causing more harm than good? A recent ...
Reality check: Dispelling the myths around the benefits of drug price controls
By Richard C. Owens with Rebecca Rosenberg and Haya Sardar June 28, 2022 PDF of paper Executive Summary Canada’s Patented ...
MLI paper finds Canada’s drug price controls hurt both innovation and Canadians’ access to medication
OTTAWA, ON (June 2, 2022): The PMPRB, a regulatory body formed in 1987, was never a principled policy initiative targeted ...
The kindest cut: Excising the Patented Medicine Prices Review Board from the Canadian body politic
By Richard C. Owens, Rebecca Rosenberg, and Haya Sardar June 2, 2022 PDF of paper Executive Summary Canada’s drug price ...
Ottawa should reset its relationship with drug developers to improve patient health: Rawson and Adams for Inside Policy
By Nigel Rawson and John Adams, May 2, 2022 On April 14, 2022, Health Minister Jean-Yves Duclos announced the federal ...
Canadians will pay a heavy price as Ottawa cuts drug costs
A new MLI commentary warns that pending and aggressive drug price control efforts could lead to major unintended consequences in ...
Time for the PMPRB to go: Nigel Rawson and Brett Skinner in the Hill Times
The PMPRB has abused its independence. The functional purpose of the PMPRB is no longer relevant, write Nigel Rawson and ...
The Patented Medicine Prices Review Board is selling Canadians a lemon: Nigel Rawson for Inside Policy
The federal government is pursuing an aggressive agenda using untried methods to regulate extremely low drug prices, writes Nigel Rawson. ...
Don’t let price controls delay access to a vaccine: Nigel Rawson and Olaf Koester in the Financial Post
Unless Ottawa guarantees the price or postpones the PMPRB revisions, manufacturers will not know whether a tendered price is compliant ...
Top News
-
COVID vaccine mandates in Canada were a mistake: Are we ready to learn the right lessons?
-
It’s Time To End Vaccine Mandates: Dr. Matthew Strauss for Inside Policy
-
Bill C-11 puts Canada’s online prosperity at risk: Peter Menzies
-
How Bill C-11 Could Open the Door to State-Controlled Media: Peter Menzies in the Epoch Times
-
Unsettling the status quo: Stirrings of reform in the school board trustee battlegrounds
